Dose Escalation Study MORAb-066 Targeting TF-expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
This study is a Phase I, first in human, dose-escalation study of MORAb-066, an
investigational humanized immunoglobulin G (IgG) monoclonal antibody (mAb) that targets
TF-expressing malignancies that include breast, pancreatic, colorectal, and non-small-cell
lung cancer (NSCLC) (adenocarcinoma). This open-label study will assess the safety,
tolerability, and pharmacokinetics of MORAb-066 administered weekly. This study will identify
the MTD when MORAb-066 is administered IV once weekly on a 28-day cycle.